Skip to content
i2E
  • Programs
    • E3
    • Bridge2
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • Bridge2
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

i2E leads $1.4M investment in Synereca

Get in Touch

September 9, 2014

Company focused on developing compounds to kill antibiotic-resistant bacteria

Contact: Sarah Seagraves,
Senior VP for Marketing
(405) 813-2403
or email [email protected]

i2E, Inc., recently closed on a $1.4 million seed capital investment in Oklahoma City-based Synereca Pharmaceuticals, which is developing ground-breaking compound that kills drug resistant bacteria.

The investment was led by the i2E-managed Oklahoma Seed Capital Fund and Accele Venture Partners with participation by the SeedStep Angels group, also managed by i2E, as well as by Oklahoma Angel investors.

With research laboratories in Oklahoma City and Chapel Hill, N.C., Synereca Pharmaceuticals is pursuing development of inhibitors that overcome and prevent the growing bacterial resistance to antibiotics.

“We’ve demonstrated that we have a compounds that without shifting toxicity make antibiotics more effective,” said Clayton Duncan, Synereca CEO.  “We’re going to use this investment to try to advance that set of compounds to improve the efficacy of the Colistin, an older antibiotic, against difficult to treat multidrug resistant bacteria. Over 90 percent of these investment dollars will go to research.”

Accele Venture Partners, LP, is a limited partnership formed to invest, together with established institutional life science investors, in the initial funding of life science companies selected and managed by Accele Biopharma, Inc.

The Oklahoma Seed Capital Fund is a state-appropriated investment fund through the Oklahoma Center for the Advancement of Science and Technology.

The SeedStep Angels group was founded by i2E in 2009 and is now the state’s largest angel investment group with more than 40 members and chapters in Oklahoma City, Tulsa, Ardmore and Muskogee.

About Synereca Pharmaceuticals

Management: Clayton Duncan, CEO; Richard Gammans, Ph.D., Chief Operation Officer; Scott Singleton, Ph.D., Chief Scientific Officer

Year Started: 2009

Location: Oklahoma City, OK and Chapel Hill, NC

Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore or increase the effectiveness of existing antibiotics.  Synereca’s development program focuses on inhibiting “RecA,” a key enzyme in bacterial DNA repair and the development and transmission of antibiotic resistance.

About i2E, Inc.:  With offices in Oklahoma City and Tulsa, OK, i2E’s nationally recognized services include business expertise and funding for Oklahoma’s emerging small businesses. i2E has more than $40 million of investment capital under management.

###

 

 

 

  • admin
    admin

More News

Loading...
Blog, i2E
09.18.23

i2E partners with MidAmerica to launch innovative pilot program fostering entrepreneurial education

Read more
headshot of Meredith Wilkerson
Blog, i2E
02.15.23

i2E Spotlight: Meredith Wilkerson, Life Sciences Venture Advisor & OKBio Director

Read more
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2023 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram

Programs

  • E3
  • Bridge2
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E